RAIN — Rain Oncology Share Price
0.000.00%
Last trade - 00:00HealthcareMicro Cap
- $44.03m
- -$33.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -113.36% | ||
| Return on Equity | -97.04% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.
Directors
- Avanish Vellanki CHM (46)
- Robert Doebele EVP (50)
- Richard Bryce EVP (63)
- Nelson Cabatuan VPR (43)
- Franklin Berger IND (71)
- Aaron Davis IND (42)
- Gorjan Hrustanovic IND (32)
- Tran Nguyen IND (47)
- Peter Radovich IND (43)
- Stefani Wolff IND (59)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 6th, 2017
- Public Since
- April 23rd, 2021
- No. of Shareholders
- 27
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 36,384,709
- Address
- 8000 Jarvis Avenue, Suite 204, NEWARK, 94560
- Web
- https://www.rainoncology.com/
- Phone
- +1 5109535559
- Auditors
- Ernst & Young LLP
Upcoming Events for RAIN
Q1 2024 Rain Oncology Inc Earnings Release
Rain Oncology Inc Annual Shareholders Meeting
Similar to RAIN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Rain Oncology share price?
As of Today at 18:17 UTC, shares in Rain Oncology are trading at $1.21. This share price information is delayed by 15 minutes.
How has the Rain Oncology share price performed this year?
Shares in Rain Oncology last closed at $1.21 and the price had moved by -87.28% over the past 365 days. In terms of relative price strength the Rain Oncology share price has underperformed the S&P500 Index by -89.41% over the past year.
What are the analyst and broker recommendations for Rain Oncology?
The overall consensus recommendation for Rain Oncology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Rain Oncology dividend yield?
Rain Oncology does not currently pay a dividend.
Does Rain Oncology pay a dividend?
Rain Oncology does not currently pay a dividend.
When does Rain Oncology next pay dividends?
Rain Oncology does not currently pay a dividend.
How do I buy Rain Oncology shares?
To buy shares in Rain Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rain Oncology?
As of the previous close price of $1.21, shares in Rain Oncology had a market capitalisation of $44.03m.
Where are Rain Oncology shares listed?
Here are the trading details for Rain Oncology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RAIN
What kind of share is Rain Oncology?
Based on an overall assessment of its quality, value and momentum Rain Oncology is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rain Oncology share price forecast for 2024?
The analyst consensus target price for shares in Rain Oncology is $1.58. That is 30.58% above the last closing price of $1.21.
Analysts covering Rain Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.48 for the next financial year.
Find out moreWhat is the trend in the Rain Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rain Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -14.64%.
As of the last closing price of $1.21, shares in Rain Oncology were trading -43.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rain Oncology PE Ratio?
The Rain Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rain Oncology?
Rain Oncology's management team is headed by:
- Avanish Vellanki - CHM
- Robert Doebele - EVP
- Richard Bryce - EVP
- Nelson Cabatuan - VPR
- Franklin Berger - IND
- Aaron Davis - IND
- Gorjan Hrustanovic - IND
- Tran Nguyen - IND
- Peter Radovich - IND
- Stefani Wolff - IND